Researcher
For individuals and research exploration
Free
- Basic platform access
- Literature intelligence preview
- Limited case analysis
Pricing & Membership
Flexible membership for oncology teams and researchers
Start with research exploration, expand into professional oncology workflows, or request a private organization deployment.
Professional
For clinicians and healthcare teams
$49/month
- Advanced case analysis
- Multidisciplinary collaboration
- Priority roadmap access
Enterprise
For hospitals, clinics, and organizations
Custom
- Clinic or hospital deployment planning
- Custom integrations
- SLA and dedicated support
- Advanced security and admin
Compare plans
Membership capabilities
| Feature | Researcher | Professional | Enterprise |
|---|---|---|---|
| Platform access | Included | Included | Included |
| Literature intelligence | Preview | Advanced | Advanced |
| AI-assisted case analysis | Limited | Advanced | Custom workflows |
| Collaboration workspace | Not included | Included | Multi-team |
| Advanced security | Standard | Standard | Advanced controls |
| Dedicated support | Community | Priority roadmap updates | Dedicated support |
| Custom integrations | Not included | Not included | Available |
FAQ
Questions from healthcare and research teams
Is OncogenTime a medical device?
OncogenTime is being developed as a decision-support and research intelligence platform. It is not intended to replace clinician judgment.
Is AI-assisted case analysis available now?
AI-assisted case analysis is part of the product roadmap and early-access development.
Do you support hospitals and research groups?
Yes. Enterprise membership is intended for organizations that need private deployment planning, security review, integrations, and dedicated support conversations.
Can organizations request a private deployment?
Yes. Organizations can request a deployment discussion for integration, security, administrative, and support requirements.
Choose the membership path that fits your oncology workflow.
Pricing shows commercial intent while early-access development continues responsibly.